Among all the selective FGFR inhibitors, AZD4547 shows potent preclinical activity in gastric adenocarcinomas with FGFR2 amplification and other gastrointestinal tumors [42, 43]. This evidence concerns the gene FGFR2 and gastric adenocarcinoma.